公开(公告)号：BRPI0908297A2

公开(公告)日：2017-02-07

申请号：BRPI0908297

申请日：2009-05-01

Applicant: ACADEMIA SINICA

Inventor： YU SU-MAY ,  KO SWEE-SUAK ,  HSING YUE-IE C ,  HO TUAN-HUA DAVID ,  LO SHUEN-FANG

IPC: A01H1/00 ,  A01H5/00 ,  C07K14/415 ,  C12N15/29 ,  C12N15/82

公开(公告)号：IL249188D0

公开(公告)日：2017-01-31

申请号：IL24918816

申请日：2016-11-24

Applicant: ACADEMIA SINICA

IPC: C07K20060101

Abstract: The present disclosure relates to a novel class of anti-HER2 monoclonal antibodies comprising a homogeneous population of anti-HER2 IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-HER2 monoclonal antibodies by Fc glycoengineering. Importantly, the antibodies of the invention have improved therapeutic values with increased ADCC activity and increased Fc receptor binding affinity compared to the corresponding monoclonal antibodies that have not been glycoengineered.

公开(公告)号：IL249184D0

公开(公告)日：2017-01-31

申请号：IL24918416

申请日：2016-11-24

Applicant: ACADEMIA SINICA

IPC: A61K20060101

Abstract: The present disclosure relates to a novel class of anti-TNFα monoclonal antibodies or antigen binding fragments comprising a homogeneous population of anti-TNFα IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-TNFα monoclonal antibodies by Fc glycoengineering. The glycoantibodies of the invention may have improved therapeutic values compared to the corresponding monoclonal antibodies that have not been glycoengineered.

公开(公告)号：IL248607D0

公开(公告)日：2016-12-29

申请号：IL24860716

申请日：2016-10-30

Applicant: ACADEMIA SINICA ,  CHI-HUEY WONG ,  JUINE-RUEY CHEN ,  CHE MA ,  CHENG-CHI WANG

Inventor： CHI-HUEY WONG ,  JUINE-RUEY CHEN ,  CHE MA ,  CHENG-CHI WANG

IPC: A61K20060101

Abstract: Immunogenic compositions comprising partially glycosylated viral glycoproteins for use as vaccines against viruses are provided. Vaccines formulated using mono-, di-, or tri-glycosylated viral surface glycoproteins and polypeptides provide potent and broad protection against viruses, even across strains. Pharmaceutical compositions comprising monoglycosylated hemagglutinin polypeptides and vaccines generated therefrom and methods of their use for prophylaxis or treatment of viral infections are disclosed. Methods and compositions are disclosed for influenza virus HA, NA and M2, RSV proteins F, G and SH, Dengue virus glycoproteins M or E, hepatitis C virus glycoprotein E1 or E2 and HIV glycoproteins gp120 and gp41.

公开(公告)号：AU2014388315A1

公开(公告)日：2016-11-17

申请号：AU2014388315

申请日：2014-10-28

Applicant: ACADEMIA SINICA ,  CHANG GUNG MEMORIAL HOSPITAL ,  DCB USA LLC ,  DEV CT BIOTECHNOLOGY

Inventor： YU ALICE L ,  YU JOHN ,  WANG YA-HUI ,  HSU CHUAN-LUNG ,  CHEN YI-CHANG ,  LOK YING-YUNG

IPC: G01N33/574

Abstract: An antibody against transmembrane coiled-coil domains protein 3 (TMCC3), or a binding fragment thereof, includes the CDR sequences set forth in the specification. A method for treating cancer includes administering to a subject in need thereof an antibody against a transmembrane coiled-coil domains protein 3 (TMCC3). The antibody binds to an epitope in an intercoil domain of TMCC3. A method of diagnosing or assessing a cancer condition includes assessing a level of expression or activity of a transmembrane coiled- coil domains protein 3 (TMCC3) in a sample, wherein an increase in the level of expression of activity of TMCC3 as compared to a standard indicates the presence of cancer stem cells in the sample.

公开(公告)号：AU2015277379A1

公开(公告)日：2016-09-08

申请号：AU2015277379

申请日：2015-06-16

Applicant: ACADEMIA SINICA ,  LIANG CHI MING

Inventor： CHEN JIUN-BO ,  SHIUNG YU-YU ,  CHANG TSE-WEN

IPC: C07K16/00 ,  A61K39/00 ,  C12P21/08

Abstract: A novel humanized anti-IgE antibody is disclosed. The antibody is capable of binding to free IgE, membrane-bound IgE on B lymphocytes, IgE bound by CD23, but not to IgE bound by high-affinity IgE.Fc receptor on mast cells. The present invention relates to the treatment of IgE-mediated diseases, including allergic asthma, allergic rhinitis, atopic dermatitis, food allergy, chronic spontaneous (idiopathic) urticaria, chronic rhinosinusitis, systemic mastocytosis, cutaneous mastocytosis, allergic bronchopulmonary aspergillosis, recurrent idiopathic angioedema, and eosinophil-associated gastrointestinal disorder by administering the anti-IgE antibody of the present invention.

公开(公告)号：IL246707D0

公开(公告)日：2016-08-31

申请号：IL24670716

申请日：2016-07-11

Applicant: ACADEMIA SINICA

IPC: C12N20060101

Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, lung, breast, mouse, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervix, ovary, and/or prostate cancer.

公开(公告)号：CA2973886A1

公开(公告)日：2016-08-04

申请号：CA2973886

申请日：2016-01-30

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  WU CHUNG-YI ,  MA CHE ,  WU HAN-CHUNG

IPC: C07K16/00 ,  A61K39/42 ,  C07K16/10 ,  C07K16/24 ,  C07K16/28 ,  C07K16/30

Abstract: The present disclosure relates to compositions and methods of use comprising antibodies or binding fragments thereof further comprising universal Fc glycoforms.

公开(公告)号：CA2972067A1

公开(公告)日：2016-07-21

申请号：CA2972067

申请日：2015-07-13

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  HSU TSUI-LING ,  LOU YI-WEI ,  LIN CHIH-WEI ,  YEH SHIHH-CHI ,  WU CHUNG-YI ,  WU HAN-CHUNG

IPC: C07K16/00 ,  A61K39/42 ,  C07K16/28 ,  C07K16/30

Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to globo H, SSEA3, and SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, skin, bone, lungs, breast, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervical, ovarian, and/or prostate cancer.

公开(公告)号：AU2015206370A1

公开(公告)日：2016-07-07

申请号：AU2015206370

申请日：2015-01-16

Applicant: ACADEMIA SINICA

Inventor： LOU YI-WEI ,  LIN CHIH-WEI ,  YEH SHIH-CHI ,  HSU TSUI-LING ,  WU CHUNG-YI ,  WU HAN-CHUNG ,  WONG CHI-HUEY

IPC: C12N5/0793

Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, lung, breast, mouse, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervix, ovary, and/or prostate cancer.